$230 Million

Roivant Sciences Ltd.

Bookrunner, February 2023

Roivant Sciences Ltd.

Roivant Sciences Ltd. (“Roivant” or the “Company”) is building the next-generation ‘‘big pharma’’ company, organized to harness modern technologies and computational tools as well as the entrepreneurial spirit of nimble biotechnology companies at scale. Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. The Company is a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. Roivant combines the team’s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. The Company deploys a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. Roivant then seeks to acquire, in-license or discover promising drug candidates against those targets or pathways. The Company’s small molecule discovery engine is powered by leading computational physics and machine learning (‘‘ML’’) capabilities for in silico drug design.

More Like This

Mar 2024

Autovista has been acquired by J.D. Power, a portfolio company of Thoma Bravo

Exclusive Financial Advisor

View Details >
Feb 2024
$430 Million

Common Stock PIPE (and Served as Financial Advisor in the Closing of Business Combination with Flame Acquisition Corp. – NYSE:FLME)

Lead Placement Agent

View Details >
Jan 2024
$250 Million

Follow-on Offering

Bookrunner

View Details >